Sulforaphane Use to Effect Inflammatory and Metabolic Changes in Virally Suppressed HIV Patients

• Status: Not yet recruiting
• Trial end date: 2022-09-21
• Target enrollment: 0
• Participant gender: All

Summary

Assess the effects of Sulforaphane supplementation in HIV patients that have achieved viral suppression.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sunshine Specialty Health Care
• Treatments: Sulforaphane

Criteria

Inclusion Criteria:

1. HIV patients on active treatment who have a suppressed viral load and have been virally suppressed for 6 months or more.

2. BMI increase of 10% or more since initiation of HIV treatment over a year period.

3. BMI equal to or greater than 30.

4. 18-70 years of age. -

Exclusion Criteria:

• 1. Cancer 2. Pregnancy or breastfeeding 3. Intolerance to cruciferous vegetables 4. Intolerance to sulforaphane 5. Gluten Intolerance 6. Creatinine > 1.3 mg/dL 7. GFR < 60 8. AST or ALT > 1.5 times upper limit of normal. 9. White cell count < 2000 cells per ml. 10. Hemoglobin < 10.5 g/dL. 11. Platelet count < 140,000 per ml.